Home › Funds › NEXTBio Capital Management LP › EVMN
NEXTBio Capital Management LP position in EVMN
EVOMMUNE INC · Health Care
NEXTBio Capital Management LP reported holding 119,063 shares of EVMN (EVOMMUNE INC) in its Q3 2026 13F filing — a position valued at US$983K, representing 0.43% of its reported portfolio and ranking #24 among its reported holdings. NEXTBio Capital Management LP has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's EVMN position evolved
NEXTBio Capital Management LP first disclosed a stake in EVMN in Q4 2025 at 228,286 shares (US$3.9M). The position peaked in Q1 2026 at 184,063 shares, worth US$4.2M. Across 4 filings, NEXTBio Capital Management LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 119,063 shares valued at US$983K. Notable position changes include a 35% trim in Q2 2026 (shares fell 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 228.29K | $3.91M | New |
| Q1 2026 | 184.06K | $4.23M | Reduce |
| Q2 2026 | 119.06K | $1.58M | Reduce |
| Q3 2026 | 119.06K | $983.46K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 109 other funds we track also report a position in EVMN — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$46.4M), EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $46.44M · Q2 2026
- EQT Fund Management S.a r.l. 5.29M sh · $43.68M · Q3 2026
- SymBiosis Capital Partners, LLC 1.28M sh · $29.45M · Q1 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $25.61M · Q2 2026
- Nan Fung Group Holdings Ltd 1.44M sh · $19.15M · Q2 2026
- Defilade Capital Management, L.P. 793.14K sh · $10.54M · Q2 2026
- Velan Capital Investment Management LP 451.25K sh · $6.00M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 594.03K sh · $4.91M · Q3 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $4.32M · Q2 2026
- Avidity Partners Management LP 75.00K sh · $996.75K · Q2 2026
- Andera Partners 97.36K sh · $804.21K · Q3 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held EVMN?
NEXTBio Capital Management LP has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in EVMN?
As of Q3 2026, NEXTBio Capital Management LP holds 119.06K shares of EVMN (EVOMMUNE INC), valued at $983.46K, representing 0.43% of its reported portfolio and ranking #24.
Has NEXTBio Capital Management LP been buying or selling EVMN?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in EVMN. The position peaked in Q1 2026 at 184.06K shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include RA CAPITAL MANAGEMENT, L.P., EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, among 109 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.